MICHELE MCINTOSH: Open Payments
NPI 1578104899 · PRINCESS ANNE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$902 in 32 payments from 13 companies in 2025. Trend: 2023 $302 · 2024 $1,140 · 2025 $902
Food & beverage: $902
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $245 |
| Vanda Pharmaceuticals Inc. | 4 | $179 |
| Lundbeck LLC | 5 | $109 |
| ABBVIE INC. | 3 | $74 |
| Janssen Pharmaceuticals, Inc | 2 | $50 |
| Alkermes, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
Products named: INGREZZA, FANAPT, REXULTI, ABILIFY ASIMTUFII, MAVYRET, INVEGA SUSTENNA, ARISTADA, Auvelity.
Industry payments across MD — which companies pay providers there.
